Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 79,060 |
|
|||||
| News | - | ||||||
| Day High | 3.29 | Low High |
|||||
| Day Low | 3.06 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings Inc | RVPH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.14 | 4.58% | 3.20 | 16:38:55 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.09 | 3.06 | 3.29 | 3.26 | 3.06 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 772 | 79,060 | US$ 3.21 | US$ 254,152 | - | 2.67 - 9.2499 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:44:00 | formt | 300 | US$ 3.20 | USD |
Reviva Pharmaceuticals Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 198.19M | 22.65M | - | 0 | -39.26M | -1.73 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Reviva Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/16/2024 | 15:32 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 2/13/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 2/13/2024 | 16:00 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
| 2/02/2024 | 15:38 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 11/17/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/17/2023 | 15:03 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 11/14/2023 | 15:12 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/30/2023 | 07:20 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/04/2023 | 16:03 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 10/04/2023 | 16:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/17/2023 | 05:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/14/2023 | 15:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RVPH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.01 | 3.29 | 2.90 | 2.99 | 105,772 | 0.19 | 6.31% |
| 1 Month | 3.43 | 3.9299 | 2.90 | 3.40 | 161,600 | -0.23 | -6.71% |
| 3 Months | 3.96 | 4.83 | 2.67 | 3.66 | 265,178 | -0.76 | -19.19% |
| 6 Months | 4.64 | 6.3001 | 2.67 | 4.24 | 426,574 | -1.44 | -31.03% |
| 1 Year | 6.99 | 9.2499 | 2.67 | 4.93 | 507,730 | -3.79 | -54.22% |
| 3 Years | 5.77 | 9.2499 | 0.53 | 3.58 | 432,149 | -2.57 | -44.54% |
| 5 Years | 9.46 | 9.61 | 0.53 | 4.69 | 495,149 | -6.26 | -66.17% |
Reviva Pharmaceuticals Description
| Reviva Pharmaceuticals Holdings Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, respiratory, and metabolic diseases. The company is currently focused on the development of its lead product candidate, RP5063, which targets schizophrenia, bipolar disorder, major depressive disorder, behavioral & psychotic symptoms, dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, and also respiratory indications such as pulmonary arterial hypertension & idiopathic pulmonary fibrosis. |
